Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
Top Page
Plus Therapeutics
(NASDAQ:PSTV)
38Underperform
Positive Factors
Clinical Trial Progress
Plus Therapeutics is progressing well in its drug development with key milestones and data points expected in 2025.
Grant Funding
The company has received substantial grants, including $18 million from the Cancer Prevention and Research Institute of Texas and $3 million from the U.S. Department of Defense.
Regulatory Designation
Rhenium (186Re) obisbemeda was granted orphan drug designation by the FDA for the treatment of breast cancer with LM.
Negative Factors
Capital Raises
Future capital raises are now estimated to occur at significantly lower share prices than previously anticipated.
Stock Performance
Stock weakness following the data presentation comes from an overreaction to a reported dose-limiting toxicity (hemiplegia).
Stock Price Target
The price target has been decreased to $10 from $32 due to a dilutive effect from lower prices of future capital raises.
Plus Therapeutics (PSTV) vs. S&P 500 (SPY)
Market Cap
$13.67M
Dividend YieldN/A
Average Volume (3M)32.33M
Price to Earnings (P/E)―
Beta (1Y)1.79
Revenue Growth52.63%
EPS Growth60.96%
CountryUS
Employees20
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.89
Shares Outstanding11,785,078
10 Day Avg. Volume45,969,541
30 Day Avg. Volume32,331,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.79
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.25Price Target Upside663.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Plus Therapeutics Business Overview & Revenue Model
Company DescriptionPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
How the Company Makes MoneyPlus Therapeutics makes money primarily through the development and potential commercialization of its proprietary radiotherapeutic products. The company's revenue model is centered around the progression of its drug candidates through clinical trials, gaining regulatory approvals, and ultimately bringing these treatments to market. Key revenue streams include potential sales of approved therapies, licensing agreements, and collaborations with other pharmaceutical companies. Plus Therapeutics may also receive funding and support through partnerships and grants that help advance its research and development efforts. As products reach market stages, revenue is generated through sales to healthcare providers and institutions treating cancer patients.
Plus Therapeutics Financial Statement Overview
Summary
Plus Therapeutics faces significant financial challenges, with declining revenue and persistent losses impacting profitability. The negative equity and high leverage pose substantial risks, while the negative cash flows highlight liquidity issues. Strategic improvements in revenue generation and cost management are crucial for financial stabilization.Income Statement
Plus Therapeutics shows a significant decline in revenue with a negative revenue growth rate from 2023 to TTM. The gross and net profit margins are negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs. The company’s revenue has been inconsistent, leading to a poor income statement rating.25
Negative
Balance Sheet
The balance sheet reveals a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, suggesting excessive leverage. ROE cannot be calculated due to negative equity, and the equity ratio also shows a negative number. Overall, the balance sheet reflects significant financial risk and a weak capital structure.30
Negative
Cash Flow
Operating and free cash flows are negative, indicating poor cash generation. The free cash flow growth rate is slightly improved from 2023 to TTM, but still negative. The operating cash flow to net income ratio suggests inefficiencies in converting income to cash. Overall, the cash flow analysis presents a challenging liquidity position.35
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 4.27M | 4.91M | 224.00K | 0.00 | 303.00K | 7.00M | Gross Profit |
| 1.13M | -4.78M | -488.00K | -66.00K | -2.40M | 1.63M | EBIT |
| -14.65M | -13.32M | -19.71M | -12.49M | -9.58M | -3.66M | EBITDA |
| -11.90M | -12.69M | -18.85M | -12.49M | -6.76M | -987.00K | Net Income Common Stockholders |
| -12.88M | -13.32M | -20.84M | -14.33M | -9.35M | -12.74M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 22.68M | 8.55M | 18.12M | 18.40M | 8.35M | 17.55M | Total Assets |
| 35.45M | 11.39M | 23.87M | 21.98M | 12.11M | 23.23M | Total Debt |
| 4.93M | 4.18M | 5.64M | 6.99M | 7.00M | 11.85M | Net Debt |
| -17.75M | -4.37M | -12.47M | -11.41M | -1.35M | -5.70M | Total Liabilities |
| 22.71M | 12.74M | 17.42M | 11.14M | 9.07M | 22.07M | Stockholders Equity |
| 12.74M | -1.35M | 6.45M | 10.84M | 3.03M | 1.16M |
| Cash Flow | Free Cash Flow | ||||
| -11.95M | -13.01M | -13.48M | -10.42M | -8.93M | -5.97M | Operating Cash Flow |
| -11.22M | -12.85M | -12.97M | -10.28M | -8.43M | -5.91M | Investing Cash Flow |
| -4.22M | -160.00K | -759.00K | -82.00K | -493.00K | 5.57M | Financing Cash Flow |
| 5.66M | 3.44M | 13.45M | 20.42M | -319.00K | 12.63M |
Plus Therapeutics Technical Analysis
Negative
0.95
Price Trends
1.10
Negative
1.16
Negative
1.36
Negative
Market Momentum
0.05
Negative
47.21
Neutral
45.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSTV, the sentiment is Negative. The current price of 0.95 is below the 20-day moving average (MA) of 1.04, below the 50-day MA of 1.10, and below the 200-day MA of 1.36, indicating a bearish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 47.21 is Neutral, neither overbought nor oversold. The STOCH value of 45.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSTV.
Plus Therapeutics Risk Analysis
Plus Therapeutics disclosed 54 risk factors in its most recent earnings report. Plus Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Plus Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $741.76M | ― | -37.72% | ― | ― | -3.08% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
46 Neutral | $52.72M | ― | -273.36% | ― | 194.23% | 45.50% | |
45 Neutral | $6.96M | ― | -30.36% | ― | ― | 86.52% | |
40 Underperform | $35.01M | ― | 41.08% | ― | -0.55% | 49.85% | |
38 Underperform | $13.67M | ― | 249.03% | ― | 52.63% | 60.96% | |
35 Underperform | $15.43M | ― | -4693.38% | ― | ― | 56.38% |
* Healthcare Sector Average
Performance Comparison
PSTV
Plus Therapeutics
0.95
-0.85
-47.22%
KPTI
Karyopharm Therapeutics
3.74
-19.96
-84.22%
ADAP
Adaptimmune Therapeutics
0.20
-1.27
-86.39%
CLRB
Cellectar Biosciences
0.32
-3.60
-91.84%
AVXL
Anavex Life Sciences
8.58
3.56
70.92%
CYCN
Cyclerion Therapeutics
2.50
-0.57
-18.57%
Plus Therapeutics Earnings Call Summary
Earnings Call Date: Mar 27, 2025 | % Change Since: -37.50% | Next Earnings Date: Apr 17, 2025
Earnings Call Sentiment Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.Highlights
Successful Financing and Partnerships
Plus Therapeutics raised $15 million in an underwritten equity financing and received $2 million in accelerated grant proceeds from CPRIT. This strengthens the balance sheet and provides funding through mid-2026. Partnerships with SpectronRX, IsoTherapeutics, RadioMedix, and ABX were also announced to ensure supply chain management for REYOBIQ.
FDA Approvals and Designations
The company received FDA approval for orphan designation of REYOBIQ for LM due to lung cancer, adding to previous orphan and fast-track designations for breast cancer.
Positive Clinical Trial Results
ReSPECT-LM Phase 1 trial showed promising safety and efficacy data, with a recommended Phase 2 dose of 44 millicuries. Results indicated a median overall survival of nine months, compared to the historical four months.
CNSide Platform Acquisition and Launch
Plus Therapeutics acquired CNSide, a CNS cancer testing platform, to increase the market potential of REYOBIQ by 2-4 times. The assay is set to launch commercially this year, starting with a limited geographic introduction.
Lowlights
Operating Loss Increase
The company reported an operating loss of $14.7 million in 2024, up from $13.3 million in 2023, primarily due to increased spending related to the ReSPECT-LM trial.
Cash and Investment Decline
Cash and investments decreased to $3.6 million at the end of 2024 from $8.6 million at the end of 2023.
Company Guidance
In the recent Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call, the company provided extensive guidance on its financial and clinical milestones. The company completed a $15 million equity financing and received $2 million in accelerated grant proceeds from CPRIT, securing funding through mid-2026. Key clinical updates included the completion of the ReSPECT-LM Phase 1 trial, establishing a recommended Phase 2 dose of 44 millicuries for their lead drug REYOBIQ, which showed promising safety and efficacy data. Plus Therapeutics plans to conduct an end-of-Phase 1 meeting with the FDA to finalize the path to approval, especially for LM related to breast cancer. Additionally, the company aims to advance its CNSide diagnostics platform, projecting significant market potential and a planned full launch within the year. Financially, the company reported a net loss of $13 million for 2024, compared to $13.3 million in 2023, and highlighted an expected 2025 grant revenue of $6 to $8 million.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.